Pfizer, BioNTech seek U.S. approval for COVID booster shots in children
Category: #healthcare  By Mateen Dalal  Date: 2022-04-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pfizer, BioNTech seek U.S. approval for COVID booster shots in children

Pharma giants Pfizer Inc. and BioNTech SE have applied to the FDA (U.S. Food and Drug Administration) for a EUA (Emergency Use Authorization) for a 10-µg booster dose of the Pfizer-BioNTech COVID-19 booster vaccine for children aged 5 to 11.

It is worth noting here that the adults receive 30 microgram doses of the Pfizer-BioNTech COVID-19 booster vaccine. Data from Phase 2/3 clinical trials that were conducted with children aged 5 to 11 years old, which was approved for EUA for this age bracket in back October 2021, was also included in the FDA application.

The results of this trial showed that a booster dose of the Pfizer-BioNTech COVID-19 vaccine resulted in developing a significant immune response in this age range, with no additional safety flags.

The two companies expect to file this data to the European Medicines Agency (EMA) as well as other regulatory organizations throughout the world for approval. For those unaware, both BioNTech and Pfizer together have developed the Pfizer-BioNTech COVID-19 vaccine, based on the latter’s patent on mRNA technology.

BioNTech caters to the marketing requirements in the U.S., the United Kingdom, the European Union, and Canada, as well as the holder of EUA if needed in the United States and other countries. Submissions will be made to seek regulatory clearance in countries where emergency use authorizations or equivalents were initially obtained.

It is also worth mentioning that it is still unclear about the need for a third vaccine dosage in the given age group. According to data from the U.S. Centers for Disease Control and Prevention, only 28% of children aged 5 to 11 years – approximately 8.2 million – are fully vaccinated.

There has also been considerable criticism about the need for boosters in younger children, considering the age group's lower risk of serious infection and hospitalization.

Source credits:

https://www.pharmalive.com/pfizer-biontech-seek-u-s-authorization-of-covid-19-booster-shot-for-younger-kids/

 

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

OpenAI to launch software tool ‘imperfect’ to identify AI-generated text
OpenAI to launch software tool ‘imperfect’ to identify AI-generated text
By Mateen Dalal

OpenAI, the American AI company and maker of the prominent chatbot, ChatGPT, has reportedly launched...

Twitter’s famed bird statue up for auction as Musk battles to pay rent
Twitter’s famed bird statue up for auction as Musk battles to pay rent
By Mateen Dalal

Twitter, the well-known social media platform now owned by Tesla boss - Elon Musk, has reportedly pl...

China: Covid-19 curbs eased in Guangzhou and Chongqing amidst protests
China: Covid-19 curbs eased in Guangzhou and Chongqing amidst protests
By Mateen Dalal

Guangzhou and Chongqing cities of China have reportedly reduced COVID-19 curbs following the clash b...